1. Japan Stocks

  2. •

    Healthcare

  3. •

    Medical - Distribution
Suzuken Co., Ltd.

Suzuken Co., Ltd.

SZUKF
Suzuken Co., Ltd.US flagOther OTC
30.30
USD
- -
- -
1.72BMarket Cap
Suzuken Co., Ltd.
SZUKF
(Other OTC)

Recent

price

30.30

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
FRC
17,666.15
18,756.16
19,106.91
20,050.39
19,864.49
22,476.23
21,653.82
22,370.31
22,783.65
24,342.72
23,863.47
25,385.89
26,904.32
29,434.73
31,625.99
- -
15,353.1
Revenue per Share
97.08
81.18
144.72
216.29
190.81
292.12
216.92
198.21
322.72
310.26
88.51
163.18
236.46
357.88
454.58
- -
169.14
Basic EPS, GAAP
85.75
514.55
423.26
-530.01
310.04
40.76
144.12
949.15
351.87
-412.56
86.75
-54.1
226.97
882.81
-1,103.32
- -
- -
Free Cash Flow per Basic Share
56.36
50.92
45.44
45.45
50.92
51.55
69.61
54.41
64.74
74.28
75.98
72.3
73.58
77.54
92.09
- -
- -
Dividend per Share
2,619.09
2,642.01
2,740.77
2,910.67
3,048.91
3,289.27
3,466.13
3,730.31
4,042.37
4,396.46
4,494.65
4,623.9
4,047.45
4,270.68
4,558.46
- -
4,680.87
Book Value per Share
2,604.42
2,647.71
2,885.97
3,075.27
3,482.48
3,759.6
3,858.5
4,120.06
4,145.63
4,416.76
4,583.44
4,613.04
4,655.54
4,997.54
5,209.31
- -
5,390.1
Tangible Book Value per Share
99
99
99
99
99
99
98
95
94
91
89
88
86
81
76
- -
78
Basic Weighted Avg Shares
1,751,961
1,859,934
1,894,611
1,988,137
1,969,683
2,228,204
2,127,076
2,124,016
2,132,345
2,213,532
2,128,478
2,239,112
2,314,828
2,386,493
2,399,952
2,486,647
1,192,021
Sales/Revenue/Turnover
0.31
0.41
0.6
0.9
0.67
1.63
0.88
0.93
1.28
1.47
0.43
0.9
1.41
1.46
1.55
1.46
1.54
Operating Margin (%)
9,656
10,975
12,239
11,932
11,718
11,930
11,720
11,042
10,772
10,719
10,179
9,560
8,639
8,563
12,053
12,341
- -
Depreciation Expense
9,627
8,050
14,350
21,447
18,920
28,960
21,308
18,820
30,204
28,213
7,895
14,393
20,345
29,016
34,496
38,136
13,132
Net Income, GAAP
42.07
49.11
38.44
39.94
35.72
35.53
33.79
34.15
33.21
32.36
36.31
35.63
33.59
32.23
31.39
29.75
33.58
Effective Tax Rate (%)
0.55
0.43
0.76
1.08
0.96
1.3
1
0.89
1.42
1.27
0.37
0.64
0.88
1.22
1.44
1.53
1.1
Profit Margin (%)
65,010
73,501
87,858
101,172
110,746
136,618
141,928
158,110
175,402
188,084
189,668
185,057
166,895
163,875
164,985
163,120
178,218
Working Capital
157
462
370
432
1,124
90
15
6
- -
- -
- -
- -
- -
- -
- -
- -
- -
LT Debt
284,851
289,758
309,826
325,994
367,797
393,947
396,495
406,424
401,623
412,706
417,909
418,061
411,524
416,427
407,419
416,010
429,861
Total Equity
1.07
1.31
2.25
3.28
2.37
5.91
3.05
3.17
4.39
5.29
1.38
3.06
5.14
5.61
6.06
6.06
2.78
Return on Invested Capital (%)
3.7
3.07
5.35
7.61
6.35
9.16
6.37
5.38
8.19
7.23
1.95
3.54
5.39
8.36
9.97
10.55
3.63
Return on Capital (%)
3.74
3.09
5.38
7.65
6.4
9.22
6.39
5.42
8.25
7.25
1.97
3.56
5.38
8.36
9.97
10.55
3.62
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Mar'24
Jun'25
Sep'25
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
78
- -
73
Market Capitalization
- -
374,329
334,686

Working Capital

FRC

•

in mil. unless spec.
Mar'24
Jun'25
Sep'25
Total Current Assets
948,293
- -
941,339
Cash, Cash Equivalents & STI
242,112
- -
184,516
Accounts Receivable, Net
539,740
- -
563,355
Inventories
142,356
- -
165,058
Total Current Liabilities
784,418
- -
763,121
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
0.56%
-0.08%
2.11%
Free Cash Flow
-35.12%
-148.02%
-118.77%
Net Income, GAAP
13.95%
39.14%
10.55%
Sales/Revenue/Turnover
1.15%
3.17%
3.61%
Total Cash Common Dividend
4.38%
1.07%
1.53%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
573,644
620,828
619,850
572,171
2,386,493
2025
- -
- -
- -
- -
2,399,952
2026
- -
- -
- -
- -
2,486,647

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
40.4
- -
- -
- -
357.88
2025
- -
- -
- -
- -
454.58
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
77.54
2025
- -
- -
- -
- -
92.09
2026
- -
- -
- -
- -
- -
Similar Companies
Galenica AG (GALNF)
Chandra Bhagat Pharma Limited (CBPL.BO)
Covetrus, Inc. (CVET)
Accendra Health, Inc. (ACH)
DocCheck AG (AJ91.DE)
Arich Enterprise Co., Ltd. (4173.TWO)
Business
Suzuken Co., Ltd. Suzuken Co., Ltd. engages primarily in pharmaceutical distribution and related healthcare services in Japan. The company operates through four main segments: pharmaceutical wholesale, which involves marketing ethical pharmaceuticals, diagnostic reagents, medical equipment, supplies, and medical foods to medical institutions and insurance pharmacies; pharmaceutical manufacturing, which focuses on research, development, manufacturing, and marketing of ethical pharmaceuticals and diagnostic reagents, particularly in areas such as diabetes and kidney diseases; insurance pharmacy, which provides dispensing operations and medication instruction for in-home patients based on prescriptions from medical institutions; and healthcare-related services, which encompass manufacturer support including transportation of medicines and comprehensive distribution for rare diseases, nursing care services, manufacturing and sales of physiological examination equipment such as electrocardiographic monitors, blood pressure monitors, and stethoscopes under the Kenz brand, publication and PR activities in medical care and health, insurance agency business, remote image diagnostic support, pharmaceutical logistics, and sales of medical books and fixtures. Suzuken Co., Ltd. maintains an extensive national network with approximately 18 distribution centers and over 11 manufacturer distribution centers, six transportation terminals, and serves more than 22,000 healthcare facilities across Japan, targeting medical institutions, pharmacies, and patients with a portfolio exceeding 80,000 pharmaceutical and medical products. Founded on November 13, 1932, by Kenzo Suzuki and headquartered at 8 Higashi Kataha-machi, Higashi-ku, Nagoya, Aichi 461-8701, Japan, the company employs 12,923 consolidated staff as of March 2025 and lists on the Prime Markets of the Tokyo, Nagoya, and Sapporo Stock Exchanges under ticker 9987. In recent developments, Suzuken Co., Ltd. launches operations at the Greater Tokyo Distribution Center in April 2024 through its collaboration with Bushu Pharmaceuticals Ltd. initiated in April 2021, featuring on-site contract manufacturing, inspection, labeling, packaging, and storage services to support foreign pharmaceutical companies entering Japan; establishes the J-ENTRY Consortium in May 2024 with Bushu Pharmaceuticals and EPS Holdings to provide one-stop support for overseas firms, covering specialty drug development, marketing approval applications, manufacturing, sales, marketing, and distribution on a contingency fee basis to reduce drug loss and financial risks; expands the Cubixx System for temperature-controlled logistics and total traceability, now in use at over 400 facilities including new versions for home use, large-capacity, and room temperature storage since 2021; and introduces VIXELL cooling box-based home delivery services in 2022 for products like Byclot Combination Intravenous Injection for hemophilia, partnering with GENie for specialized drug delivery. These initiatives advance Suzuken Co., Ltd.'s transformation into a health creation enterprise, enhancing specialty drug distribution for rare diseases and cell/gene therapies, global logistics via partnerships like World Courier since 2018, and sustainable supply chain efficiency while pursuing ESG-focused growth.